PAH

Current drugs attempt to reduce the pulmonary artery pressure by dilating the pre-capillary arteries; these drugs are vasodilators; they have increased the 50% survival rate from 3 to 5 years, and they are very expensive.

All these vasodilator drugs act via intracellular cAMP or cGMP, or block endothelial receptors, and they do not modify the disease and at best improve the quality of life available to some modest degree.

Despite these drugs availability, the one-year mortality for high-risk patients is 10 -30% and they do not provide a significant change to the quality of life.

The ReversPAH treatment is expected to reverse the disease and dramatically improve exercise capacity.

This new treatment is expected to reopen previously-occluded arteries, thus reducing the pulmonary artery pressure by 30% or greater – and consequently improving right heart function.

This approach is unique as instead of marginally increasing blood flow through vasodilation or a lung transplant to extend life, we induce cell death in death - resistant uncontrolled growing endothelial cells and lumen-obliterating cells in the lungs of patients – resulting in much higher blood flow.

We expect from responding IPAH patients a substantial drop in the pulmonary artery pressure within 30 to 60 days after beginning of the treatment.